CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jupe, E. R.
Right arrow Articles by Dell'Orco, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jupe, E. R.
Right arrow Articles by Dell'Orco, R. T.

Cell Growth & Differentiation, Vol 7, Issue 7 871-878, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3' untranslated region mutations

ER Jupe, XT Liu, JL Kiehlbauch, JK McClung and RT Dell'Orco
Noble Center for Biomedical Research, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.

The evolutionarily conserved prohibitin gene is located on human chromosome 17q21, and two alleles have been identified. Our previous studies characterizing prohibitin in immortalized cells, classified into four complementation groups (A-D) based on the ability of whole-cell hybrids to become senescent, have suggested that it has tumor suppressor activity in group B cells. Only the cell lines assigned to group B are sensitive to the antiproliferative activity of prohibitin, and all are homozygous for an allele designated B because of its exclusive association with this group. Prohibitin genotyping of 22 breast cancer cell lines identified 17 homozygous for the B allele, 5 homozygous for the non-B allele, and no heterozygotes. Four of these cell lines were chosen for further characterization of prohibitin. In cell proliferation assays, the homozygous B breast cancer cell lines (BT-20, SK-BR-3, and MCF7) are all inhibited from traversing the cell cycle following the introduction of wild-type prohibitin transcripts. The cell line homozygous for the alternative non-B allele (BT-549) is not inhibited by transcripts. All of the breast cancer cell lines overexpress the longer form of the prohibitin mRNA (1.9 kb) and the protein. Mutational analysis of the protein-coding region detected no mutations in any of the lines. However, BT-20, SK-BR-3, and MCF7 cells are all mutated in the final 200 bases of the 3' untranslated region (3'UTR) exclusive to the 1.9-kb transcript, but BT-549 cells had no alterations in this region of the 3'UTR. Functional mapping experiments performed in the mutated SK-BR-3 line showed that the wild-type 3'UTR alone is sufficient to inhibit cell cycle progression, indicating that the antiproliferative activity of the prohibitin transcript is localized to this region. Overall, our results show that most (80%) of the cell lines derived from breast tumors have a common prohibitin genotype, suggesting that they belong to the same group of immortalized cells, group B. The results also show that the prohibitin 3'UTR exhibits the characteristics of a trans-acting regulatory RNA (riboregulator), the tumor suppressor activity of which is inactivated by mutation in group B immortalized cells.


This article has been cited by other articles:


Home page
J. Virol.Home page
J.-F. Lan, X.-C. Li, J.-J. Sun, J. Gong, X.-W. Wang, X.-Z. Shi, L.-J. Shi, Y.-D. Weng, X.-F. Zhao, and J.-X. Wang
Prohibitin Interacts with Envelope Proteins of White Spot Syndrome Virus and Prevents Infection in the Red Swamp Crayfish, Procambarus clarkii
J. Virol., December 1, 2013; 87(23): 12756 - 12765.
[Abstract] [Full Text] [PDF]


Home page
Cancer DiscoveryHome page
F. A. Karreth and P. P. Pandolfi
ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go Awry
Cancer Discovery, October 1, 2013; 3(10): 1113 - 1121.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Patel, S. K. Chatterjee, V. Vrbanac, I. Chung, C. J. Mu, R. R. Olsen, C. Waghorne, and B. R. Zetter
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
PNAS, February 9, 2010; 107(6): 2503 - 2508.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. Osman, C. Merkwirth, and T. Langer
Prohibitins and the functional compartmentalization of mitochondrial membranes
J. Cell Sci., November 1, 2009; 122(21): 3823 - 3830.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Rastogi, B. Joshi, P. Dasgupta, M. Morris, K. Wright, and S. Chellappan
Prohibitin Facilitates Cellular Senescence by Recruiting Specific Corepressors To Inhibit E2F Target Genes
Mol. Cell. Biol., June 1, 2006; 26(11): 4161 - 4171.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Rastogi, B. Joshi, G. Fusaro, and S. Chellappan
Camptothecin Induces Nuclear Export of Prohibitin Preferentially in Transformed Cells through a CRM-1-dependent Mechanism
J. Biol. Chem., February 3, 2006; 281(5): 2951 - 2959.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
I. G. Campbell, J. Allen, and D. M. Eccles
Prohibitin 3' Untranslated Region Polymorphism and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1273 - 1274.
[Full Text]


Home page
Cancer Res.Home page
S. Manjeshwar, D. E. Branam, M. R. Lerner, D. J. Brackett, and E. R. Jupe
Tumor Suppression by the Prohibitin Gene 3'Untranslated Region RNA in Human Breast Cancer
Cancer Res., September 1, 2003; 63(17): 5251 - 5256.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
L. G. J. Nijtmans, L. de Jong, M. Artal Sanz, P. J. Coates, J. A. Berden, J. W. Back, A. O. Muijsers, H. van der Spek, and L. A. Grivell
Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins
EMBO J., June 1, 2000; 19(11): 2444 - 2451.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. M. Montano, K. Ekena, R. Delage-Mourroux, W. Chang, P. Martini, and B. S. Katzenellenbogen
An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
PNAS, June 8, 1999; 96(12): 6947 - 6952.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
T. L. Sit, A. A. Vaewhongs, and S. A. Lommel
RNA-Mediated Trans-Activation of Transcription from a Viral RNA
Science, August 7, 1998; 281(5378): 829 - 832.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.